In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in patients with previously treated, advanced non‒small-cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% and ≥1%. We report 5-year efficacy/safety follow-up for the KEYNOTE-010 study.
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
Novello, Silvia;
2021-01-01
Abstract
In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in patients with previously treated, advanced non‒small-cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% and ≥1%. We report 5-year efficacy/safety follow-up for the KEYNOTE-010 study.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
PIIS1556086421021729.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
598.59 kB
Formato
Adobe PDF
|
598.59 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
